Vanda Pharmaceuticals Inc.
VNDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001347178
No open-market purchases or sales by Vanda Pharmaceuticals Inc. insiders were filed in the last 90 days; 172 institutions reported holding it in 13F filings for Q2 2026, worth $304.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Vanda Pharmaceuticals Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Vanda Pharmaceuticals Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Dugan Richard W | Director | 219,054 | Jun 8, 2026 | 1 |
| Chrousos Phaedra | Director | 164,950 | Jun 8, 2026 | 1 |
| Ward Anne Sempowski | Director | 160,667 | Jun 8, 2026 | 1 |
| Mitchell Stephen Ray | Director | 112,846 | Jun 8, 2026 | 2 |
| Honore Tage | Director | 135,069 | Jun 8, 2026 | 2 |
| Duncan Charles Cliff | Director | 98,701 | Jun 8, 2026 | 2 |
| McGuire Daniel Patrick | SVP, GC and Secretary | 109,982 | Jun 8, 2026 | 1 |
| Polymeropoulos Mihael Hristos | President and CEO | 2,704,496 | Mar 4, 2026 | 2 |
| Birznieks Gunther | SVP, Business Development | 494,197 | Mar 4, 2026 | 2 |
| Williams Timothy | SVP & General Counsel | 377,450 | Mar 4, 2026 | 2 |
| Wijkstrom Joakim | SVP, Chief Marketing Officer | 333,469 | Mar 4, 2026 | 2 |
| Moran Kevin Patrick | SVP, CFO & Treasurer | 411,380 | Mar 4, 2026 | 2 |
| Watkins Thomas | Director | 63,064 | Jun 3, 2022 | 0 |
| Jones Aranthan II | Chief Corp. Affairs Officer | 81,980 | Sep 17, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 (view filing) | Feb 23 | 1 day | Honore TageDirector | SSale | −30.0K | $8.03 | −$240.9K | −24.3%93.5K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Polymeropoulos Mihael HristosPresident and CEO | SSale | −156.2K | $8.17 | −$1.28M | −5.5%2.70M after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Birznieks GuntherSVP, Business Development | SSale | −42.4K | $8.27 | −$350.9K | −7.9%494.2K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Williams TimothySVP & General Counsel | SSale | −42.4K | $8.27 | −$350.9K | −10.1%377.4K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Wijkstrom JoakimSVP, Chief Marketing Officer | SSale | −30.8K | $8.27 | −$254.7K | −8.5%333.5K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Moran Kevin PatrickSVP, CFO & Treasurer | SSale | −42.4K | $8.27 | −$351.0K | −9.4%411.4K after |